HomeFinanceThe market value of BioMarin Pharmaceutical Inc. (BMRN) Stock is expected to...

The market value of BioMarin Pharmaceutical Inc. (BMRN) Stock is expected to soar in the coming months

Canaccord Genuity raised the price target for the BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock to “a Hold”. The rating was released on January 18, 2023, according to finviz. We previously noted in another research note published on October 31, 2022 by Oppenheimer that upgraded the stock from a Perform to an Outperform with a price target of $110 for BMRN stock. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $110. The stock was resumed by Wedbush, who disclosed in a research note on June 13, 2022, to Neutral and set the price objective to $70. In their research brief published April 25, 2022, Morgan Stanley analysts upgraded the BioMarin Pharmaceutical Inc. stock from Equal-Weight to Overweight with a price target of $113.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) raised 2.13% to close Tuesday’s market session at $113.82, higher as compared to yesterday’s close. The stock price fluctuated between $111.26 and $114.02 throughout the trading session with the volume trading being 1202216 shares, which represented a significant variation when compared to the three months average volume of 1.58 million shares. The firm’s stock price fluctuated 1.85% within the last five trades and 8.79% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 33.36% in the last 6 months and 26.45% was added to its value over the previous 3 months. BMRN stock is trading at a margin of 5.75%, 11.95% and 27.58% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, BMRN deals in the Healthcare domain. The stock is trading -0.85 percent below its 52-week high and 60.92 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 43.22. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does BioMarin Pharmaceutical Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at 5.40 percent and the profit margin is 4.20 percent, and the company has reported a gross margin of 76.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $20.86 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is 288.15. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 72.36. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 10.39 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 4.62, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

BIENAIME JEAN JACQUES, the Chief Executive Officer at BioMarin Pharmaceutical Inc. (BMRN) has sold 10,000 shares of firm on Jan 17 at a price of $111.55 against the total amount of $1.12 million. In another inside trade, BIENAIME JEAN JACQUES, Chief Executive Officer of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) sold 10,000 shares of the firm on Jan 13 for a total worth of $1.12 million at a price of $112.25. An inside trade which took place on Jan 13, EVP, Chief Financial Officer of BioMarin Pharmaceutical Inc. Mueller Brian sold 2,500 shares of firm against total price of $0.29 million at the cost of $114.50 per share.



Please enter your comment!
Please enter your name here

Recent Post